Tecentriq misses mark in ovarian cancer trial
The drug did not extend progression-free survival in patients with newly diagnosed advanced stage ovarian cancer
Read More
Tag: atezolizumab
Roche’s Tecentriq shows promise in early triple-negative breast cancer
Less patients who received the Tecentriq combination before surgery had evidence of tumour tissue detectable at the time of surgery
Read More
Roche’s Tecentriq/Avastin combo wins US approval
Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen cleared to treat unresectable or metastatic liver cancer
Read More
NICE u-turn backs Roche’s Tecentriq for small-cell lung cancer
The drug giant agreed a new price for Tecentriq with NHS England and Improvement
Read More
NICE u-turn backs Roche’s Tecentriq for triple negative breast cancer
Tecentriq is the first and only immune checkpoint inhibitor which has been deemed a cost effective use of NHS resources for this patient group
Read More
New US nod for Roche’s Tecentriq in NSCLC
This is Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the US
Read More
Keytruda misses key lung cancer survival endpoint
The drug significantly improved progression-free survival, but missed its overall survival endpoint.
Read More
Tecentriq hit with draft NICE rejection
The UK watchdog says that the “long-term benefit on overall survival is uncertain”.
Read More
Tecentriq combo proves effective in bladder cancer
The drug improved progression-free survival to 8.2 months from 6.3 months.
Read More
EU approval for Tecentriq combo
The approval of the monoclonal antibody was based on results from the Phase III IMpassion130 study.
Read More
Roche bags small cell lung cancer nod for Tecentriq
Roche’s Tecentriq has won US clearance for use in combination with carboplatin and etoposide (chemotherapy) as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) in the US, offering patients the first new treatment in more than 20 years.
Read More
Priority review for Roche’s Tecentriq/Abraxane combo
US regulators are undertaking a priority review of Roche’s Tecentriq in combination with Abraxane for the treatment of triple-negative breast cancer.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
